2^ndInternational Conference and Exhibition on Pharmaceutical Nanotechnology and Nanomedicine March 20-21, 2019 New York, USA

Biography:

Yucel Baspinar studied Pharmacy at Free University Berlin, Germany and started as a research assistant at the same Institute in the Department of Pharmaceutical Biochemistry, Biopharmacy and Biotechnology with his Ph.D. thesis (2005-2009) entitled as “nano and microemulsions for the topical application of poorly soluble immune suppressive". After his Ph.D., he worked as Post-Doc for Prof. Burkhard Kleuser in the same Faculty, Department of Pharmacology and Toxicology in an EFRE (European Fund for Regional Development) project entitled with “Nanocarriersystems for dermatotherapy" (2009-2010). 2011-2013 he worked as Head of Drug Development and Quality Control Laboratory and in Biosimilar Laboratory in the Center for Drug Research & Development and Pharmacokinetic Applications at the Ege University in Izmir, Turkey. 2013- now he is Assistant Professor in the Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, Ege University. The major research areas are Pharmaceutical Formulations of protein drugs and monoclonal antibodies prepared by the recombinant DNA technology and biosimilars

Abstract:

23% of the worldwide cancer-related death rate is due to lung cancer, more than the sum of breast, colon and prostate cancer. A great deal in common for almost each cancer type, including lung cancer, is an overexpression of the apoptosis inhibitor survivin. For improving the chemotherapy several strategies were performed. Previously, ultrasound sensitive nanobubbles containing paclitaxel, survivin-siRNA and survivin inhibitor sepantronium bromide (YM155), respectively, were developed against A549 lung cancer cells. The paclitaxel-loaded nanobubbles had a particle size of 309nm and a zeta potential of 34mV, the paclitaxel and YM155 loaded nanobubbles had a particle size of 57nm and a ZP of 47mV, while the PTX and siRNA loaded nanobubbles had a particle size of 252nm and a ZP of 27mV. The cytotoxicity studies revealed promising results and encouraged for further investigations. The aim of this study was to evaluate the siRNA complexation, serum stability, gene silencing efficiency, and Apoptosis. The developed nanobubbles were able to form a complex with survivin-siRNA and protected the siRNA from nucleases. The gene silencing efficiency and Apoptosis were evaluated, with and without ultrasound exposure, by qPCR and Apoptosis kits and showed that NB formulations were able to silence survivin expression and induce apoptosis in the A549 cell line.

Acknowledgement: This study has been financially supported by TUBITAK under grant code 116S213

Biography:

Abstract:

Background: Glioblastoma (GBM) is the most aggressive primary adult brain tumor with only 14.6 months of median survival. Carrier nanoparticles have emerged as a novel strategy for chemotherapeutic delivery, yet penetration of the blood-brain barrier (BBB) and tumor retention remain significant hurdles. The evolution of paramagnetic nanoparticles (PMNPs) shows promise for reliable, magnetically-targeted drug delivery, and coupled with a lipopolysaccharide-coating (LPS-PMNPs) allows for concurrent, reversible BBB disruption.

Biography:

Jigisha P Badheka MD Anaesthesiology Working as an Associate Professor, In Department of Anaesthesiology, PDU Medical College, Rajkot Instructor for ACLS, BLS. PG Certificate course QM & AHO (Quality Management & accreditation of health Care organization) by AHA, and  Disaster Management course by IGNOU. Wide experience in all the fields of anesthesia, Tutor for 11/2 yrs 1995-97 Class 1 anaesthesiology for 3 yrs.1997-99 Assistant professor for 7 yrs.1999- 2007 Associate professor since 2007 till date. Internal and external examiner since last 10yrs. Publications for national and international journals. Speaker for state and national conference.

Abstract:

The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. Novel Drug Delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. Whereas the Targeted drug delivery, sometimes called smart drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. It has advantages like the reduction in the frequency of the dosages, having a more uniform effect of the drug, reduction of the adverse effect of drugs and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult and the reduced ability to adjust the dosages. Newer intravenous drugs used for TIVA having a short duration of action so, fast recovery to maintain plasma level and to achieve the constant targeted level of sedation, analgesia, and anaesthesia targeted release system is useful which releases the drug in a dosage form. I will discuss a review of target controlled infusion total intravenous anaesthesia in India.

Biography:

Selvie S. Ticoalu is Gynecology specialists in Bandung, West Java at the Advent Bandung Hospital and teaches as lecturers AKBID Makariwo

Abstract:

Diabetes Mellitus is one of the causes of mortality and morbidity in all countries, where there are 3.5-4.3% of the world's population affected by diabetes mellitus. Based on data from the World Health Organization (WHO), the number of people with diabetes mellitus in the world reaches 285 million and is estimated to be more than 430 million by 2030. Type 2 diabetes mellitus (not insulin-related) is the most common, 95% of all cases of diabetes mellitus. The aim of the study was to determine the effect of giving Gedi leaf decoction (Abelmoschus manihot L.) to decrease blood sugar levels in pregnant women in northern Halmahera in 2018. The research method used was quasi-experimental with the design of one group pretest-posttest. The population in this study were 10 pregnant women at the Tiberias Tobelo clinic, with a sampling technique using a total sampling of 10 pregnant women with blood sugar. The results of the study showed that the average blood sugar levels in pregnant women before giving the decoction of Gedi leaves (Abelmoschus manihot L.) was 109.79mg/dL, and the average value of blood sugar in pregnant women after Gedi leaf decoction (Abelmoschus manihot L.) is 108.12mg/dL, the results of the analysis test with Paired sample T-Test obtained a significance value (p) of 0.002 significance value p<0.05. The conclusion that the average decrease in blood sugar levels in pregnant women is 1.67mg/dL, the statistical test results obtained that the effect of giving the leaves of Gedi leaves (Abelmoschus manihot L.) to pregnant women with blood sugar.

Biography:

David Guerrero in 2015, joined the research team of Dr. Michael Chorny at The Children’s Hospital of Philadelphia working on new drug delivery systems for treating arterial restenosis and cancer. Among other projects, he has worked on developing new strategies to target and treat aggressive pediatric solid tumors using polymeric nanoparticles formulated with novel mutual prodrugs (co-drugs). His research has contributed to a recent paper in Clin Cancer Res on enhanced intratumoral delivery of camptothecin-mitocan co-drugs for the treatment of high-risk neuroblastoma.

Abstract:

Nanomedicine-based delivery strategies have the potential to improve the therapeutic performance of a variety of anticancer agents. However, their clinical translation has been hampered by difficulty in achieving stable drug entrapment within nanocarriers, together with controlled release directly in the tumor tissue. In this study, we evaluated an experimental strategy that combines in situ activatable camptothecin-mitocan fusion molecules (co-drugs) and sub-100nm sized biodegradable nanoparticles (NP) derived using a nanoprecipitation-based formulation process. A series of reversibly hydrophobized co-drugs of a potent camptothecin agent, SN38, with tocol mitocans exhibiting a range of hydrolytic activation rates were encapsulated in 85±36nm sized NP with high efficiency (93±2% entrapment yield) using the optimized procedure. NP loaded with a phenolic ester co-drug were found to be most effective against both chemo-naïve and chemoresistant NB cells under conditions modeling different levels of exposure experienced by NB cells within the tumor. Phenolic carbonate and aliphatic ester designs were found to be notably less efficient. In an in-vivo model of previously untreated disease [IMR-32 orthotopic xenograft], nanocarriers with phenolic ester co-drug administered over 4 weeks [10mg/kg, twice a week] induced tumor regression and completely inhibited tumor growth over a 26-week period. The same co-drug/nanocarrier formulation tested against multidrug-resistant NB [BE(2)-C orthotopic xenograft] potently suppressed tumor growth and extended animal survival up to 7 weeks, in contrast to a marginal and transient effect of the clinically used SN-38 precursor, irinotecan [event-free survival of 3 weeks vs. 2 weeks in ‘no treatment’ and drug-free NP groups]. We conclude that camptothecin-mitocan co-drugs can be rationally designed as therapeutic cargoes for nanocarrier-based therapy of aggressive malignancies. The co-drug/nanocarrier combination strategy proven effective in preclinical testing experiments in this study holds promise as a treatment for high-risk NB and potentially can be extended to other pediatric and adult solid tumors

Biography:

Fremiot J.Mascarenhas, Qualifications: MBBS. From M. P. Shah Medical College, Jamnagar. Diploma in Anaesthesiology from M.P.Shah Medical College, Jamnagar. Currently practicing as a consultant Anaesthesiologist in city of Bhavnagar, Gujarat,India since last 25 years. The main field of interest are laparoscopy and Bariatric Anaesthesia and postoperative pain relief Post held: Secretary, Bhavnagar Anaesthesiologist' Association from 2011 to 2017. Presently Hon. Secretary, Bhavnagar Medical Association from 2015. Successfully Organized West Zone Anaesthesia Conference-ISACONGUJARAT2016 at Bhavnagar as Organizing Secretary

Abstract:

Transdermal drug delivery refers to a system in which a fixed amount of drug is delivered across the skin over a period of time to the bloodstream so as to maintain a therapeutic level of that drug. This method of drug delivery is painless and has excellent compliance in both pediatric and geriatric age group as it is pain-free and hassle free and does not need any specialized equipment for its use. Transdermal method of drug delivery has a great many advantages over other conventional routes of drug administration such as oral, intramuscular, intravenous. Medication applied in form of a fixed-dose adhesive patch that is applied to the skin surface and is absorbed through the pores of the skin and delivered in the bloodstream in a controlled way. The main objective of this painless route of administering a drug is to provide a therapeutic dose level of drug in the bloodstream with the minimal patient to patient variation while limiting the side effects if the same were to be administered by any other route.

Biography:

Gershon Golomb is a Full Professor of Pharmaceutics at the School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem. His works for many years has focused on drug delivery systems. His studies have developed controlled-release implantable and injectable drug/gene delivery systems; from hypothesis to in-vivo studies. He is an expert in targeted nanoparticles (polymeric-based and liposomes) for the treatment of cancer, cardiovascular disorders, and inflammatory-associated pathologies.

Abstract:

The mononuclear phagocytic system (MPS) is a part of the immune system that consists of phagocytic cells, primarily monocytes, and macrophages. Both circulating monocytes and neutrophils phagocyte debris, and foreign particles in the blood including particulate drug delivery systems. Inflammation characterizes several pathological disorders including cardiovascular disorders and cancer, and the inflammatory cascade involves significant infiltration of phagocytic cells. The propensity of monocytes for rapid phagocytosis of particulate matter provides a rational approach for delivering drugs in inflammatory-associated disorders. In this presentation, we will review therapeutic as well as diagnostic approaches mediated via specially designed nanoparticles (NPs), which are avidly internalized by circulating monocytes. Monocytes can serve as a courier of specific NPs to the CNS, bypassing the blood-brain barrier (BBB), effectively transporting drugs that are brain- impermeable. Liposomal delivery of quantum dots (QDs) enables an efficient fluorescent signal with no toxicity, in animal models of cardiovascular and cancer disorders. In addition, we will present recent results, unpublished, on the accumulation and retention of QDs in a mammary carcinoma model, following systemic administration, in comparison to passive delivery by the enhanced permeability and retention effect (EPR). The developed NPs delivery systems represent a novel approach for effective theranostic of inflammatory-associated disorders including cardiovascular, brain, and cancer diseases.

Biography:

Arend L Mapanawang has completed his Ph.D. from the Department of Pharmacy, College of Health Sciences, Yayasan Medika Mandiri Foundation, Halmahera, Indonesia. He is the Director of College of Health Sciences (STIKES Halmahera), Medika Mandiri Foundation, Halmahera, Indonesia. He is the Head of Internal Medicine Departement of Bethesda Hospital in Tobelo North Halmahera, North Moluccas.

Abstract:

Cancer is one of the diseases that the death rate is high because it has not found a drug that heals it completely. Researches continue to be developed incorrectly one is to develop a (Zingiberaceae) and leaf pangi (pangiense) vegetables consumed daily in Minahasa North Sulawesi by MTT and HPLC test methods golobe 6.5mg/ml and pangi 150mg/ml performed to see antioxidant activity and anticancer, can be seen the result that encourages use as protection or prevention is consumed as a health supplement either as an antioxidant or serves as a precaution against a variety of free radicals that have the potential to trigger the cells cancer in the body. FTIR test and spectrometer analysis and MTT Test, with the result of comparison of 1307- Fori 7/7 VS MCF-7 with IC₅₀ (µg/ml) 1307,015 with positive control of cisplatin IC₅₀ (µg/ml) 8,028. This shows golobe provides low activity but as supplements are very useful for protection or prevention. Likewise with a combination of pangi and golobe (dry simplicia) IC₅₀ (µg/ml) 5860,470. This shows activity is weak but when given each IC₅₀ golobe has more activity strong for cancer activity. At FTIR test leaf pangi has the highest peak 3510,6, intensity 16,36, base (H) 3747,85, base (L) 3497,09, area 141,06, Corona 113,25. Pangi leaves also have activity antioxidant and anticancer and has an antiretroviral activity that the herbs are from the grass become a new hope for prevention and even treatment in the future come.

Biography:

Maykel A. Kiling is Research lecturer and study program chairman at STIKES Halmahera

Abstract:

Golobe halmahera (Hornstedtia alliacea) is one type of farmer that has health benefits. The use of golobe halmahera is a source of energy when hunting, used when there are injuries and infections and this plant grows in the tropics including Halmahera. This research was conducted to identify chemical compounds contained in extra acids of methanol golobe (Hornstedtia alliacea). The design of this study was purely experimental conducted at the STIKES Halmahera pharmacy laboratory. The separation technique is maceration using methanol as a liquid dancer and the gas chromatography-mass spectrometry method is used to identify the compounds contained in the golobe halmahera methanol extract. The results showed that golobe halmahera contained alpha-cubebene 2.04%, myristaldehyde 1.33%, ethyl (9Z) -9-octadecenoate 2.13%, tricosane 3.78%, heptadecane 6.75%, pentacosane 28, 29%, heptafluorobutanoic acid, 3.15% heptadecyl ester, ethanol, 2- (octadecyloxy) 14.76%, all-trans-squalene 2.55%, 9-tricosane 6.10%, heptadecane10.05%, 17- hexadecyltetratriacotane 1.94%, (9Z) -9-tricosane 7.00%, benzenamine 2,3,4,5,6-penthacloro 7,96%.

Biography:

Muhammad Jehangir has 13 years diversified experience of Quality Control, Quality Assurance, Registration Affairs, Product development and Pharmaceutical manufacturing, Process Planning, Method development, Method validation, Statistical Methodology, Process & Cleaning Validation, Equipment Validation etc. Certificate Courses on cGMP, cGLP, Process Validation, CTD Documents, ISO 9001:2008, 13485-2003,14001-2004 have strong scientific, analytical, statistical, managerial and training skills. Currently, he is working as a Senior Manager Quality Control and validation for Novamed Pharmaceuticals. It is toll manufacturing-oriented company, manufacturing of companies like Getz Pharma, ICI, SEARLE, Macter, Ray, and for Sanofi-Aventis. He is also looking after the Quality of Novamed Healthcare, the nutraceutical and cosmeceutical manufacturing plant.

Abstract:

The evaluation of pharmaceutical raw materials and finished products for impurities and degradation products is an essential part of the drug development and manufacturing testing process. Additionally, toxicological information must be obtained on any drug-related impurity that is present at a concentration of greater than 0.1% of that of the active pharmaceutical ingredient (API). In pharmaceutical QC and manufacturing, impurity analysis has traditionally been performed by HPLC with UV, PDA, or MS detection. As it is essential to detect and measure all of the impurities in the sample, it is necessary to have a high-resolution separation process. This usually involves long analysis times resulting in low throughput. As candidate pharmaceutical compounds become more potent and are dosed at lower and lower levels, ever more sensitive assays are needed to detect and measure impurities. The low throughput of HPLC can become the rate-limiting step in product release testing or process evaluation. Since much of the process of impurity identification involves the coupling of LC to sophisticated MS, any reduction in analysis time will result in more efficient use of these significant investments. Analytical technology advances such as UPLC and UPC offer significant improvements in throughput and sensitivity, with benefits to the process of product release and identification of drug-related impurities. The most characteristic feature of the development in the methodology of pharmaceutical and biomedical analysis during the past 25 years is that HPLC became undoubtedly the most important analytical method for identification and quantification of drugs, either in their active pharmaceutical ingredient or in their formulations during the process of their discovery, development, and manufacturing.

Biography:

Muhammad Shahid Khan has got more than 18 years of experience in the pharmaceutical industry in different posts. He is currently working as Plant Manager in NovaMed Pharmaceuticals (Pvt) Ltd., a local firm but also manufacturing products for many multinational companies like Sanofi Aventis, ICI, Getz Pharma, and Searle. He is overall responsible for the whole plant. He has attended many training workshops, exhibitions and technical seminars in Pakistan and abroad. He has got training from France. He has visited many countries of the world for training and to attend exhibitions.

Abstract:

The purpose of this research study was formulation development and in-vitro characterization of orodispersible tablets of Piroxicam and Lidocaine HCl along with the development and validation of the novel method of simultaneous estimation of both the drugs on HPLC. The aim was to develop a product that will provide immediate relief from the pain of dental origin, due to the local action of lidocaine in the mouth and also produce long-lasting analgesia by piroxicam after absorption. Orodispersible tablets of Piroxicam and Lidocaine HCl were developed by direct compression method. FTIR spectroscopy was used to study drug-drug and drugs-excipients compatibility. The FTIR spectra showed that there was no interaction between the two drugs and also between the drugs and excipients which proved that all the ingredients are compatible. The assay method for simultaneous estimation of both the drugs on HPLC was developed successfully. The developed method was also validated by following ICH guidelines.